Shares of Hims & Hers Health shot higher in premarket trading after reports emerged that Novo Nordisk intends to offer its weight-loss medicines through Hims' telehealth platform. The move represents an apparent reconciliation between the two companies following a dispute that had previously severed their commercial relationship.
By 09:08 GMT on Monday, Hims stock, which has fallen by roughly 51% so far this year, jumped more than 44% in premarket trading. Novo Nordisk's shares in Copenhagen also rose, climbing approximately 1%.
Sources indicated that the two companies could make a formal announcement as soon as Monday. Under the proposed arrangement, Novo's obesity treatments would be made available to patients through Hims' telehealth services - effectively restoring access that had lapsed when the relationship unraveled last year. That earlier breakdown followed accusations by Novo that Hims was continuing to market compounded versions of Novo's drugs.
Tensions flared further earlier this year when Novo Nordisk filed suit against Hims in February after Hims introduced a copycat oral version of Wegovy. Novo argued the product infringed patents related to the active ingredient used in its high-profile brands Ozempic and Wegovy.
Analysts reacted to the reported development as both surprising and potentially beneficial for Hims' market outlook. Leerink analyst Michael Cherny called the news "both a surprise and an unabashed positive for HIMS' stock," and said it could avert what had appeared to be "a protracted legal process that could include a full trial." At the same time, Cherny cautioned that the update did not amount to a full resolution for Hims' ability to reclaim prior growth, maintaining a Market Perform rating and writing, "even with this positive news, we do not see this as a clearing event for HIMS to fully recapture its growth potential and thus maintain our Market Perform rating."
Morgan Stanley analyst Craig Hettenbach emphasized the potential market impact of reduced legal and regulatory uncertainty. He noted that a new partnership could remove one of the largest overhangs on the company, writing that "any reduction in those risks could lead to a strong rebound in the heavily shorted stock."
The broader context for the dispute includes a period of supply shortages for branded weight-loss drugs, during which several telehealth firms offered lower-cost alternatives. Although those shortages have since eased and some sellers were expected to discontinue copycat products, a number of providers have continued to market modified versions by adjusting dosages or ingredients in an effort to differentiate from the branded therapies.
At this stage, the reported potential agreement would reinstate a channel for Novo's obesity drugs on Hims' platform and reduce prominent legal and regulatory uncertainties for the telehealth company, while analysts caution that material questions remain about Hims' longer-term ability to regain earlier growth trajectories.